Issue: March 2017
March 21, 2017
1 min read
Save

Reduced surgical time seen with custom trabecular metal prosthesis for treatment of bone sarcoma

Issue: March 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN DIEGO — A presenter at the American Academy of Orthopaedic Surgeons Annual Meeting, here, said a custom-made trabecular metal spacer he and his colleagues developed was a more reliable alternative to allograft to reconstruct large pelvic bone defects due to tumor because the device was associated with a shorter operative time and helped spare patients’ hip abductors intraoperatively.

“I think this is a good option for the future,” Davide Donati, MD, said.

Davide Donati

Donati presented early experience with a series of eight patients with pelvic sarcomas — four of which were Ewing’s sarcoma — treated with the custom-made pelvic prosthesis at his institution in Bologna, Italy, between August 2013 and March 2016.

According to Davide, the implants took about 35 days to fabricate and were implanted using special bone osteotomy-cutting jigs. The prostheses fit in the bone gap that was left after tumor resection.

Patients lost a mean of 3 units of blood intraoperatively and they achieved Musculoskeletal Tumor Society Scores that exceeded 80%, he said. Results showed a mean operative time of less than 4 hours, Donati noted.

“We had much less complications than we had with the bone allograft. We improved the bone-prosthesis contact, restored the original anatomy and so, we improved functional activity,” he said. “Now the question is how stable [is it] and the integrity of the implant during that.” Susan M. Rapp

Reference:

Cevolani L, et al. Paper #513. Presented at: American Academy of Orthopaedic Surgeons Annual Meeting; March 14-18, 2017; San Diego.

Disclosure: Donati reports no relevant financial disclosures.